Offshore
Photo
Wall St Engine
OpenAI plans to start shipping its first AI device—designed with Jony Ive—by late 2026, per CEO Sam Altman via WSJ. Altman told staff the goal is to reach 100M units faster than any new product ever, calling it “the biggest thing we’ve ever done."
It's not a phone or glasses—think a "third device" to sit next to your laptop and phone, fully aware of your environment, designed to reduce screen time.
tweet
OpenAI plans to start shipping its first AI device—designed with Jony Ive—by late 2026, per CEO Sam Altman via WSJ. Altman told staff the goal is to reach 100M units faster than any new product ever, calling it “the biggest thing we’ve ever done."
It's not a phone or glasses—think a "third device" to sit next to your laptop and phone, fully aware of your environment, designed to reduce screen time.
tweet
Offshore
Photo
Hidden Value Gems
Discount to NAV has still predictive power for listed PEs, according to this study. https://t.co/gjllUvSUoK
tweet
Discount to NAV has still predictive power for listed PEs, according to this study. https://t.co/gjllUvSUoK
tweet
Wall St Engine
Today's Key Events (All EST) — 05/22/2025
All Day: G7 Finance Summit
08:00: Fed's Barkin
08:30: US Initial Jobless Claims
09:45: US S&P PMI Flash
10:00: US Existing Home Sales
11:00: Kansas City Fed Manufacturing
13:00: US 10-Year TIPS Auction
14:00: Fed's Williams
Before Open 👇
06:00: Atour Lifestyle $ATAT
06:30: Advance Auto Parts $AAP
06:45: BJ's Wholesale Club, Inc. $BJ
06:45: CSW Industrials, Inc. $CSWI
06:45: Titan Machinery Inc. $TITN
06:55: Kanzhun Limited $BZ
07:00: Analog Devices, Inc. $ADI
07:00: Lightspeed Commerce Inc. $LSPD
07:10: Thermon Group Holdings, Inc. $THR
08:00: Ralph Lauren Corporation $RL
09:00: Williams-Sonoma, Inc. $WSM
After Hours 👇
04:00: Workday, Inc. $WDAY
04:00: Autodesk, Inc. $ADSK
04:00: Intuit Inc. $INTU
04:00: Ross Stores Inc. $ROST
04:05: Deckers Brands $DECK
04:05: StepStone Group Inc. $STEP
04:05: Cavco Industries Inc. $CVCO
04:05: ePlus, Inc. $PLUS
04:15: Copart Inc. $CPRT
After Close: Fidelity Southern Corp. New $LION
After Close: Corporación América Airports S.A. $CAAP
tweet
Today's Key Events (All EST) — 05/22/2025
All Day: G7 Finance Summit
08:00: Fed's Barkin
08:30: US Initial Jobless Claims
09:45: US S&P PMI Flash
10:00: US Existing Home Sales
11:00: Kansas City Fed Manufacturing
13:00: US 10-Year TIPS Auction
14:00: Fed's Williams
Before Open 👇
06:00: Atour Lifestyle $ATAT
06:30: Advance Auto Parts $AAP
06:45: BJ's Wholesale Club, Inc. $BJ
06:45: CSW Industrials, Inc. $CSWI
06:45: Titan Machinery Inc. $TITN
06:55: Kanzhun Limited $BZ
07:00: Analog Devices, Inc. $ADI
07:00: Lightspeed Commerce Inc. $LSPD
07:10: Thermon Group Holdings, Inc. $THR
08:00: Ralph Lauren Corporation $RL
09:00: Williams-Sonoma, Inc. $WSM
After Hours 👇
04:00: Workday, Inc. $WDAY
04:00: Autodesk, Inc. $ADSK
04:00: Intuit Inc. $INTU
04:00: Ross Stores Inc. $ROST
04:05: Deckers Brands $DECK
04:05: StepStone Group Inc. $STEP
04:05: Cavco Industries Inc. $CVCO
04:05: ePlus, Inc. $PLUS
04:15: Copart Inc. $CPRT
After Close: Fidelity Southern Corp. New $LION
After Close: Corporación América Airports S.A. $CAAP
tweet
Offshore
Photo
Wall St Engine
Duolingo $DUOL CFO Matt says AI is the key to pushing the app beyond language learning. The company launched 148 new AI-developed courses in April and a beta chess course—all aimed at creating a "human tutor in your pocket." AI features like Lily have also boosted premium subs https://t.co/QDZNMCPsrO
tweet
Duolingo $DUOL CFO Matt says AI is the key to pushing the app beyond language learning. The company launched 148 new AI-developed courses in April and a beta chess course—all aimed at creating a "human tutor in your pocket." AI features like Lily have also boosted premium subs https://t.co/QDZNMCPsrO
tweet
Offshore
Photo
Wall St Engine
Manchester United shares are trading lower after the club lost 1-0 to Tottenham Hotspur in the Europa League final. https://t.co/jZI84lYtv9
tweet
Manchester United shares are trading lower after the club lost 1-0 to Tottenham Hotspur in the Europa League final. https://t.co/jZI84lYtv9
tweet
Wall St Engine
BofA Reiterates Underperform Rating on $HIMS, PT $28
Analyst comments: "Observed sales data continues to weaken sequentially. Observed sales growth year-over-year decelerated 6ppts from March with sales down 6% month-over-month (3% adjusted for days) and GLP-1 sales declined for the 2nd consecutive month. While early in the quarter, April trends suggest upside to 2Q Street estimates with Online revenue of $552MM–$578MM vs. VA consensus of $539.2MM. However, this assumes compounded semaglutide sales remain consistent through June as a percentage of sales. Additionally, modeling revenue from the Wegovy partnership which began in May would likely make future projections more challenging. Meanwhile, growth ex-GLP-1s remains relatively steady and could be benefitting from oral weight loss demand as customers switch from commercial GLP-1 doses. The 503B semaglutide compounding deadline on May 22nd could prompt the FDA or NVO to work toward limiting the scale of personalized compounding. Ultimately, the ability to meet the FY25 guide hinges on the scale of personalized GLP-1s (refer to our 1Q note), which is a catch-22 as higher GLP-1 sales could reintroduce litigation risk into the model. If sales of compounded semaglutide moderates in May/June, core growth and Wegovy would need to provide the offset which could prove challenging. Maintain Underperform."
Analyst: Michael Cherny
tweet
BofA Reiterates Underperform Rating on $HIMS, PT $28
Analyst comments: "Observed sales data continues to weaken sequentially. Observed sales growth year-over-year decelerated 6ppts from March with sales down 6% month-over-month (3% adjusted for days) and GLP-1 sales declined for the 2nd consecutive month. While early in the quarter, April trends suggest upside to 2Q Street estimates with Online revenue of $552MM–$578MM vs. VA consensus of $539.2MM. However, this assumes compounded semaglutide sales remain consistent through June as a percentage of sales. Additionally, modeling revenue from the Wegovy partnership which began in May would likely make future projections more challenging. Meanwhile, growth ex-GLP-1s remains relatively steady and could be benefitting from oral weight loss demand as customers switch from commercial GLP-1 doses. The 503B semaglutide compounding deadline on May 22nd could prompt the FDA or NVO to work toward limiting the scale of personalized compounding. Ultimately, the ability to meet the FY25 guide hinges on the scale of personalized GLP-1s (refer to our 1Q note), which is a catch-22 as higher GLP-1 sales could reintroduce litigation risk into the model. If sales of compounded semaglutide moderates in May/June, core growth and Wegovy would need to provide the offset which could prove challenging. Maintain Underperform."
Analyst: Michael Cherny
tweet